Management of hyperlipidemia in patients on peritoneal dialysis: Current approaches

Kidney International

Volumn 70, Issue SUPPL. 103, 2006, Pages

  Prichard, S S ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICODEXTRIN; SEVELAMER;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DYSLIPIDEMIA; ENZYME DEFECT; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; KIDNEY DISEASE; MYALGIA; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SAFETY; CHRONIC KIDNEY FAILURE;

HUMANS; HYPERLIPIDEMIAS; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS;

EID: 39049174094     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001926     Document Type: Article

References (33)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(Suppl 3): S112-S119.
2. Attman PO, Samuelsson O, Johansson AC et al. Dialysis modalities and dyslipidemia. Kidney Int 2003; 63(Suppl 84): S110-S112.
3. Attman PO, Samuelsson OG, Moberly J et al. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int 1999; 55: 1536-1542.
4. Avram MM, Fein PA, Antignani A et al. Cholesterol and lipid disturbances in renal disease: the natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis. Am J Med 1989; 87: 55N-60N.
5. Futatsuyama M, Oiwa T, Komatsu Y. Correlation between oxidized low-density lipoprotein and other factors in patients on peritoneal dialysis. Adv Perit Dial 2002; 18: 192-194.
6. Johansson AC, Samuelsson O, Attman PO et al. Dyslipidemia in peritoneal dialysis - relation to dialytic variables. Perit Dial Int 2000; 20: 306-314.
7. Kronenberg F, Konig P, Neyer U et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995; 6: 110-120.
8. Kronenberg F, Lingenhel A, Neyer U et al. Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int 2003; 63(Suppl 84): S113-S116.
9. Llopart R, Donate T, Oliva JA et al. Triglyceride-rich lipoprotein abnormalities in CAPD-treated patients. Nephrol Dial Transplant 1995; 10: 537-540.
10. Moberly JB, Attman PO, Samuelsson O et al. Alterations in lipoprotein composition in peritoneal dialysis patients. Perit Dial Int 2002; 22: 220-228.
11. O'Neal D, Lee P, Murphy B, Best J. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis 1996; 27: 84-91.
12. Prichard SS. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol 2003; 14(Suppl 4): S315-S320.
13. Siamopoulos KC, Elisaf MS, Bairaktari HT et al. Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis. Perit Dial Int 1995; 15: 342-347.
14. Sniderman A, Cianflone K, Kwiterovich Jr PO et al. Hyperapobetalipoproteinemia: the major dyslipoproteinemia in patients with chronic renal failure treated with chronic ambulatory peritoneal dialysis. Atherosclerosis 1987; 65: 257-264.
15. Maggi E, Bellazzi R, Gazo A et al. Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int 1994; 46: 869-876.
16. Shoji T, Nishizawa Y, Nishitani H et al. Roles of hypoalbuminemia and lipoprotein lipase on hyperlipoproteinemia in continuous ambulatory peritoneal dialysis. Metab Clin Exp 1991; 40: 1002-1008.
17. Prichard S, Cianflone K, Sniderman A. The role of the liver in the pathogenesis of hyperlipidemia in patients with end-stage renal disease treated with continuous ambulatory peritoneal dialysis. Perit Dial Int 1996; 16(Suppl 1): S207-S210.
18. Misra M, Reaveley DA, Ashworth J et al. Six-month prospective cross-over study to determine the effects of 1.1% amino acid dialysate on lipid metabolism in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1997; 17: 279-286.
19. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group [see comment]. New Engl J Med 1995; 333: 1301-1307.
20. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators [see comment]. New Engl J Med 1996; 335: 1001-1009.
21. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease [see comment]. New Engl J Med 2005; 352: 1425-1435.
22. Anonymous. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) [see comment]. Lancet 1994; 344: 1383-1389.
23. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis [see comment] [erratum appears in N Engl J Med 2005; 353: 1640]. N Engl J Med 2005; 353: 238-248.
24. Prichard S, Fried L. Hypercalcemia in a peritoneal dialysis patient. Perit Dial Int 2001; 21: 420-427.
25. Kidney Disease Outcomes Quality Initiative G. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003; 41(Suppl 3): I-IV.
26. Saltissi D, Morgan C, Rigby RJ, Westhuyzen J. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis [see comment]. Am J Kidney Dis 2002; 39: 283-290.
27. Nishizawa Y, Shoji T, Emoto M et al. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients. Clin Nephrol 1995; 43: 268-277.
28. Harris KP, Wheeler DC, Chong CC. Atorvastatin in CAPD Study Investigators. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney Int 2002; 61: 1469-1474.
29. Chertow GM, Burke SK, Raggi P, for the Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients [see comment]. Kidney Int 2002; 62: 245-252.
30. Holmes CJ, Shockley TR. Strategies to reduce glucose exposure in peritoneal dialysis patients. Perit Dial Int 2000; 20(Suppl 2): S37-S41.
31. Martikainen T, Teppo AM, Gronhagen-Riska C, Ekstrand A. Benefit of glucose-free dialysis solutions on glucose and lipid metabolism in peritoneal dialysis patients. Blood Purif 2005; 23: 303-310.
32. Furuya R, Odamaki M, Kumagai H, Hishida A. Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients. Nephrol Dial Transplant 2006; 21: 494-498.
33. Bredie SJ, Bosch FH, Demacker PN et al. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int 2001; 21: 275-281.